Tang Xin, Wu Jiaojiao, Liang Jiangtao, Yuan Changfeng, Shi Feng, Ding Zhongxiang
Hangzhou Health Promotion Research Institute, Hangzhou Wuyunshan Hospital, Hangzhou, China.
Department of Research and Development, Shanghai United Imaging Intelligence Co., Ltd., Shanghai, China.
Front Oncol. 2022 Aug 23;12:991102. doi: 10.3389/fonc.2022.991102. eCollection 2022.
This study aimed to study the diagnostic efficacy of positron emission tomography (PET)/magnetic resonance imaging (MRI), computed tomography (CT) and clinical metabolic parameters in predicting the histological classification of lung adenocarcinoma (ADC) and squamous cell carcinoma (SCC).
PET/MRI, CT and clinical metabolic data of 80 patients with lung ADC or SCC were retrospectively collected. According to the pathological results from surgery or fiberscopy, the patients were diagnosed with lung ADC (47 cases) or SCC (33 cases). All 80 patients were divided into a training group (64 cases), an internal testing group (8 cases) and an external testing group (8 cases) in the ratio of 8:1:1. Nine models were constructed by integrating features from different modalities. The Gaussian classifier was used to differentiate ADC and SCC. The prediction ability was evaluated using the receiver operating characteristic curve. The area under the curve (AUC) of the models was compared using Delong's test. Based on the best composite model, a nomogram was established and evaluated with a calibration curve, decision curve and clinical impact curve.
The composite model (PET/MRI + CT + Clinical) owned the highest AUC values in the training, internal testing and external testing sets, respectively. In the training set, significant differences in the AUC were found between the composite model and other models except for the PET/MRI + CT model. The calibration curves showed good consistency between the predicted output and actual disease. The decision curve analysis and clinical impact curves demonstrated that the composite model increased the clinical net benefit for predicting lung cancer subtypes.
The composite prediction model of PET/MRI + CT + Clinical better distinguished ADC from SCC pathological subtypes preoperatively and achieved clinical benefits, thus providing an accurate clinical diagnosis.
本研究旨在探讨正电子发射断层扫描(PET)/磁共振成像(MRI)、计算机断层扫描(CT)及临床代谢参数在预测肺腺癌(ADC)和肺鳞癌(SCC)组织学分类中的诊断效能。
回顾性收集80例肺ADC或SCC患者的PET/MRI、CT及临床代谢数据。根据手术或纤维支气管镜检查的病理结果,将患者诊断为肺ADC(47例)或SCC(33例)。80例患者按8∶1∶1的比例分为训练组(64例)、内部测试组(8例)和外部测试组(8例)。通过整合不同模态的特征构建9种模型。采用高斯分类器区分ADC和SCC。利用受试者工作特征曲线评估预测能力。采用德龙检验比较各模型的曲线下面积(AUC)。基于最佳复合模型,建立列线图,并通过校准曲线、决策曲线和临床影响曲线进行评估。
复合模型(PET/MRI + CT + 临床)在训练集、内部测试集和外部测试集中分别拥有最高的AUC值。在训练集中,除PET/MRI + CT模型外,复合模型与其他模型的AUC存在显著差异。校准曲线显示预测输出与实际疾病之间具有良好的一致性。决策曲线分析和临床影响曲线表明,复合模型增加了预测肺癌亚型的临床净效益。
PET/MRI + CT + 临床的复合预测模型能更好地在术前区分ADC和SCC病理亚型并实现临床效益,从而提供准确的临床诊断。